John Corbin

Dr. Corbin joins BigHat from Tizona Therapeutics where he served as Chief Technology Officer, leading the antibody discovery and engineering, protein sciences and CMC of therapeutic antibodies for all Tizona pipeline programs. Prior to joining Tizona, Dr. Corbin oversaw antibody discovery and engineering at Gilead Sciences for multiple therapeutic areas including oncology and HIV. Previously, he was at XOMA serving in several roles and most notably led XOMA’s insulin receptor antagonist program (XOMA 358) from inception through lead selection, which was acquired by Rezolute Bio (RZLT) and completed Phase 2 clinical trials. Dr. Corbin received his Ph.D. in Biology from University of California at Santa Cruz and completed his postdoctoral research at the University of Colorado at Boulder. Dr. Corbin has published in numerous peer-reviewed journals and is an inventor on many antibody patents. Several molecules created by Dr. Corbin are undergoing clinical development today.